Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR- JCARE Announcement on the Capital Increase of The Holding Sub-Subsidiary – LivzonBio

Time:2023-11-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Fourth Extraordinary General Meeting

Time:2023-11-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Termination of Livzon Group's Planned Spin-off and Listing of Its Subsidiary on the ChiNext Market and Application for the Listing on the NEEQ

Time:2023-11-10

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Proposed Selection of Certain Company's Pharmaceuticals in the National Volume-based Procurement

Time:2023-11-06

Ad hoc announcement pursuant to Art-JCARE Announcement on Obtaining the Approval Notice for Drug Clinical Trials

Time:2023-10-13

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Third Extraordinary General Meeting

Time:2023-10-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Third Extraordinary General Meeting

Time:2023-09-21

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Sencond Extraordinary General Meeting

Time:2023-09-15

Ad hoc announcement pursuant to Art-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for Aripiprazole Microspheres for Injection

Time:2023-09-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Vice President of The Company

Time:2023-09-08

< 1...101112...16 >